Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC

Condition:   Recessive Dystrophic Epidermolysis Bullosa Interventions:   Drug: Rigosertib Sodium;   Other: Quality-of-Life Assessment Sponsors:   Thomas Jefferson University;   Onconova Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials